Skin collagen pentosidine and fluorescence in diabetes were predictors of retinopathy progression and creatininemia increase already 6 years after punch-biopsy

Clinical Biochemistry

Volumn 49, Issue 3, 2016, Pages 225-231

  Sternberg, Michel ^a   M'bemba, Jocelyne ^b   Urios, Paul ^a,c   Borsos, Anne Marie ^a,d   Selam, Jean Louis ^b   Peyroux, Jacques ^a   Slama, Gérard ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔTEL DIEU   (France)

^c BICHAT HOSPITAL   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

Author keywords

Creatininemia; Diabetic nephropathy; Diabetic retinopathy; Fluorescence; Microalbuminuria; Pentosidine; Progression of microvascular complications; Skin collagen

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; COLLAGEN; CREATININE; HEMOGLOBIN A1C; HYDROXYPROLINE; PENTOSIDINE; ARGININE; BIOLOGICAL MARKER; LYSINE;

ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; CREATININEMIA; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; FEMALE; FLUORESCENCE; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PUNCH BIOPSY; ADULT; ALBUMINURIA; ANALOGS AND DERIVATIVES; BIOPSY; BLOOD; CASE CONTROL STUDY; CHEMISTRY; DIABETIC ANGIOPATHY; DISEASE COURSE; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; SPECTROFLUOROMETRY;

ADULT; ALBUMINURIA; ARGININE; BIOMARKERS; BIOPSY; CASE-CONTROL STUDIES; COLLAGEN; CREATININE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; FLUORESCENCE; HUMANS; LONGITUDINAL STUDIES; LYSINE; MALE; MIDDLE AGED; SKIN; SPECTROMETRY, FLUORESCENCE;

EID: 84957434783     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2015.10.011     Document Type: Article

References (30)

1. Aoki S., Hasegawa G., Shigeta H., Obayashi H., Fujii M., Kimura F., et al. Crossline levels in serum and erythrocyte membrane proteins from patients with diabetic nephropathy. Diabetes Res. Clin. Pract. 2000, 48:119-125.
2. Beisswenger P.J., Moore L.L., Brinck-Johnsen T., Curphey T.J. Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J. Clin. Invest. 1993, 92:212-217.
3. Boehm B.O., Schilling S., Rosinger S., Lang G.E., Lang G.K., Kientsch-Engel R., et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macula oedema. Diabetologia 2004, 47:1376-1379.
4. Chiarelli F., Catino M., Tumini S., Cipollone F., Mezzetti A., Vanelli M., et al. Advanced glycation end products in adolescents and young adults with diabetic angiopathy. Pediatr. Nephrol. 2000, 14:841-846.
5. Cockroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
6. ETDRS Early treatment diabetes retinopathy study research group. Grading diabetic retinopathy from stereoscopic color fundus photographs. An extension of the modified Airlie House Classification. ETDRS report number 10. Ophthalmology 1991, 98:786-806.
7. Genuth S, Sun.W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM; DCCT Skin Collagen Ancillary Study Group Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005, 54:3103-3111.
8. Genuth S., Sun W., Cleary P., Gao X., Sell D.R., Lachin J., DCCT/EDIC Research Group, Monnier V.M. Skin advanced glycation end products glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes 2015, 64:266-278.
9. Hammes H.P., Martin S., Federlin K., Geisen K., Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc. Natl. Acad. Sci. U. S. A. 1991, 88:11,555-11,558.
10. McCance D.R., Dyer D.G., Dunn J.A., Bailie K.E., Thorpe S.R., Baynes J.W., et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J. Clin. Invest. 1993, 91:2470-2478.
11. Meerwaldt R., Graaff R., Oomen P.H., Links T.P., Jager J.J., Alderson N.L., et al. Simple non-invasive assessment of advanced glycation end product accumulation. Diabetologia 2004, 47:1324-1330.
12. Miura J., Yamagishi S., Uchigata Y., Takeuchi M., Yamamoto H., Makita Z., et al. Serum levels of non carboxymethyllysine advanced glycation end products are correlated to severity of microvascular complications in patients with type 1 diabetes. J. Diabetes Complicat. 2003, 17:16-21.
13. Monnier V.M., Bautista O., Kenny D., Sell D.R., Fogarty J., Dahms W., Cleary P.A., Lachin J., Genuth S., DCCT Skin Collagen Ancillary Study Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes 1999, 48:870-880.
14. Monnier V.M., Vishwanath V., Frank K.E., Elmets C.A., Dauchot P., Kohn R.R. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N. Engl. J. Med. 1986, 314:403-408.
15. Noordzij M.J., Lefrandt J.D., Graaff R., Smit A.J. Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol. Ther. 2011, 13:165-170.
16. Noordzij M.J., Lefrandt J.D., Graaff R., Smit A.J. Skin autofluorescence and glycemic variability. Diabetes Technol. Ther. 2012, 12:581-585.
17. Noordzij M.J., Mulder D.J., Oomen P.H., Brouwer T., Jager J., Castro Cabezas M., et al. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a Multi-centre study. Diabet. Med. 2012, 29:1556-1561.
18. Odetti P., Fogarty J., Sell D.R., Monnier V.M. Chromatographic quantification of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes 1992, 41:153-159.
19. Ono Y., Aoki S., Ohnishi K., Yasuda T., Kawano K., Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res. Clin. Pract. 1998, 41:131-137.
20. Peyroux J., Sternberg M. Advanced glycation end products (AGEs): pharmacological inhibition in diabetes. Pathol. Biol. 2006, 54:405-419.
21. Sell D.R., Lapolla A., Odetti P., Fogarty J., Monnier V.M. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 1992, 41:1286-1292.
22. Soulis T., Cooper M.E., Sastra S., Thallas V., Panagiotopoulos S., Bjerrum O.J., et al. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997, 40:1141-1151.
23. Sugiyama S., Miyata T., Ueda Y., Tanaka H., Maeda K., Kawashima S., et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J. Am. Soc. Nephrol. 1998, 9:1681-1688.
24. Wautier M.P., Massin P., Guillausseau P.J., Huijberts M., Levy B., Boulanger E., et al. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetics patients. Diabete Metab. 2003, 29:44-52.
25. Verzijl N., DeGroot J., Thorpe S.R., Bank R.A., Shaw J.N., Lyons T.J., et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J. Biol. Chem. 2000, 275:39,027-39,031.
26. Vlassara H., Stricker L.J., Teicherg S., Fuh H., Li Y.M., Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:11,704-11,708.
27. Weiss M.F., Erhard P., Kader-Attia F.A., Wu Y.C., Deoreo P.B., Araki A., et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int. 2000, 57:2571-2585.
28. Weissman S., Tschudy D.P., Bacchus H., Eubanks M. Use of precursor product relationships in determining serum albumin half-life. J. Lab. Clin. Med. 1961, 57:136-146.
29. Woessner J.F. The determination of hydroxyproline and protein samples containing small proportions of this imino acid. Arch. Biochem. Biophys. 1961, 93:440-447.
30. Wolffenbuttel B.H., Giordano D., Founds H.W., Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996, 347:513-515.